Literature DB >> 21199931

Susceptibility of clinical Mycobacterium tuberculosis isolates to a potentially less toxic derivate of linezolid, PNU-100480.

J W C Alffenaar1, T van der Laan, S Simons, T S van der Werf, P J van de Kasteele, H de Neeling, D van Soolingen.   

Abstract

Susceptibility of clinical Mycobacterium tuberculosis isolates to PNU-100480 and linezolid was evaluated by the MGIT 960 system. The isolates had various susceptibilities to isoniazid (INH), rifampin, ethambutol, and streptomycin. The mean MIC for PNU-100480 was 3.2 times lower than that for linezolid. Therefore, PNU-100480 is a promising candidate to be developed further as an adjunct in the treatment of multidrug- and extensively drug-resistant tuberculosis (MDR/XDR-TB).

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21199931      PMCID： PMC3067097          DOI： 10.1128/AAC.01297-10

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  25 in total

1.  In vitro activity of moxifloxacin, levofloxacin, gatifloxacin and linezolid against Mycobacterium tuberculosis.

Authors:  J C Rodríguez; M Ruiz; M López; G Royo
Journal:  Int J Antimicrob Agents       Date:  2002-12       Impact factor: 5.283

2.  Pharmacokinetics and whole-blood bactericidal activity against Mycobacterium tuberculosis of single doses of PNU-100480 in healthy volunteers.

Authors:  Robert S Wallis; Wesley M Jakubiec; Vikas Kumar; Annette M Silvia; Darcy Paige; Dessislava Dimitrova; Xiaoxi Li; Lynn Ladutko; Sheldon Campbell; Gerald Friedland; Mark Mitton-Fry; Paul F Miller
Journal:  J Infect Dis       Date:  2010-09-01       Impact factor: 5.226

3.  Biomarker-assisted dose selection for safety and efficacy in early development of PNU-100480 for tuberculosis.

Authors:  Robert S Wallis; Wesley Jakubiec; Vikas Kumar; Gabriella Bedarida; Annette Silvia; Darcy Paige; Tong Zhu; Mark Mitton-Fry; Lynn Ladutko; Sheldon Campbell; Paul F Miller
Journal:  Antimicrob Agents Chemother       Date:  2010-11-15       Impact factor: 5.191

4.  Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis--authors' response.

Authors:  Won-Jung Koh; Tae Sun Shim
Journal:  J Antimicrob Chemother       Date:  2009-09-10       Impact factor: 5.790

5.  Multidrug-resistant tuberculosis: long-term treatment outcome in the Netherlands.

Authors:  W A Geerligs; R Van Altena; D Van Soolingen; T S Van Der Werf
Journal:  Int J Tuberc Lung Dis       Date:  2000-08       Impact factor: 2.373

6.  Hematologic effects of linezolid: summary of clinical experience.

Authors:  Stanton L Gerson; Sheldon L Kaplan; Jon B Bruss; Vu Le; Felix M Arellano; Barry Hafkin; David J Kuter
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

7.  Synthesis and in vitro antimycobacterial activity of novel 3-(1H-pyrrol-1-yl)-2-oxazolidinone analogues of PNU-100480.

Authors:  Gianluca Sbardella; Antonello Mai; Marino Artico; Roberta Loddo; Maria Grazia Setzu; Paolo La Colla
Journal:  Bioorg Med Chem Lett       Date:  2004-03-22       Impact factor: 2.823

8.  Predictors and outcome of multidrug-resistant tuberculosis.

Authors:  N Salomon; D C Perlman; P Friedmann; S Buchstein; B N Kreiswirth; D Mildvan
Journal:  Clin Infect Dis       Date:  1995-11       Impact factor: 9.079

9.  In vitro activities of linezolid against clinical isolates of Mycobacterium tuberculosis that are susceptible or resistant to first-line antituberculous drugs.

Authors:  Luis Alcalá; María Jesús Ruiz-Serrano; Cristina Pérez-Fernández Turégano; Darío García De Viedma; Marisol Díaz-Infantes; Mercedes Marín-Arriaza; Emilio Bouza
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191

Review 10.  Infectiousness, reproductive fitness and evolution of drug-resistant Mycobacterium tuberculosis.

Authors:  S Borrell; S Gagneux
Journal:  Int J Tuberc Lung Dis       Date:  2009-12       Impact factor: 2.373
View more
  15 in total

1.  Population pharmacokinetic/pharmacodynamic analysis of the bactericidal activities of sutezolid (PNU-100480) and its major metabolite against intracellular Mycobacterium tuberculosis in ex vivo whole-blood cultures of patients with pulmonary tuberculosis.

Authors:  Tong Zhu; Sven O Friedrich; Andreas Diacon; Robert S Wallis
Journal:  Antimicrob Agents Chemother       Date:  2014-03-31       Impact factor: 5.191

Review 2.  Investigational antimicrobial agents of 2013.

Authors:  Michael J Pucci; Karen Bush
Journal:  Clin Microbiol Rev       Date:  2013-10       Impact factor: 26.132

3.  Sterilizing activities of novel combinations lacking first- and second-line drugs in a murine model of tuberculosis.

Authors:  Kathy Williams; Austin Minkowski; Opokua Amoabeng; Charles A Peloquin; Dinesh Taylor; Koen Andries; Robert S Wallis; Khisimuzi E Mdluli; Eric L Nuermberger
Journal:  Antimicrob Agents Chemother       Date:  2012-04-02       Impact factor: 5.191

Review 4.  Drug-resistance in Mycobacterium tuberculosis: where we stand.

Authors:  Amanda Mabhula; Vinayak Singh
Journal:  Medchemcomm       Date:  2019-06-11       Impact factor: 3.597

Review 5.  Molecule Property Analyses of Active Compounds for Mycobacterium tuberculosis.

Authors:  Vadim Makarov; Elena Salina; Robert C Reynolds; Phyo Phyo Kyaw Zin; Sean Ekins
Journal:  J Med Chem       Date:  2020-04-20       Impact factor: 7.446

Review 6.  The future for early-stage tuberculosis drug discovery.

Authors:  Edison S Zuniga; Julie Early; Tanya Parish
Journal:  Future Microbiol       Date:  2015       Impact factor: 3.165

Review 7.  Targeting multidrug-resistant tuberculosis (MDR-TB) by therapeutic vaccines.

Authors:  Satria A Prabowo; Matthias I Gröschel; Ed D L Schmidt; Alena Skrahina; Traian Mihaescu; Serap Hastürk; Rotislav Mitrofanov; Edita Pimkina; Ildikó Visontai; Bouke de Jong; John L Stanford; Père-Joan Cardona; Stefan H E Kaufmann; Tjip S van der Werf
Journal:  Med Microbiol Immunol       Date:  2012-11-10       Impact factor: 3.402

8.  Contribution of the nitroimidazoles PA-824 and TBA-354 to the activity of novel regimens in murine models of tuberculosis.

Authors:  Rokeya Tasneen; Kathy Williams; Opokua Amoabeng; Austin Minkowski; Khisimuzi E Mdluli; Anna M Upton; Eric L Nuermberger
Journal:  Antimicrob Agents Chemother       Date:  2014-10-20       Impact factor: 5.191

Review 9.  Antituberculosis therapy for 2012 and beyond.

Authors:  Michael Lauzardo; Charles A Peloquin
Journal:  Expert Opin Pharmacother       Date:  2012-02-15       Impact factor: 3.889

10.  Chemotherapeutic interventions against tuberculosis.

Authors:  Neeraj Shakya; Gaurav Garg; Babita Agrawal; Rakesh Kumar
Journal:  Pharmaceuticals (Basel)       Date:  2012-06-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.